Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) and Medical Marijuana (OTCMKTS:MJNA – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, dividends, earnings and risk.
Institutional & Insider Ownership
24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 0.0% of Medical Marijuana shares are held by institutional investors. 9.5% of Gyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Gyre Therapeutics and Medical Marijuana”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Gyre Therapeutics | $116.59 million | 6.61 | $5.03 million | ($0.21) | -32.90 |
| Medical Marijuana | N/A | N/A | N/A | ($0.01) | -0.03 |
Gyre Therapeutics has higher revenue and earnings than Medical Marijuana. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Medical Marijuana, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Gyre Therapeutics and Medical Marijuana, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Gyre Therapeutics | 2 | 0 | 2 | 0 | 2.00 |
| Medical Marijuana | 0 | 0 | 0 | 0 | 0.00 |
Gyre Therapeutics currently has a consensus price target of $17.00, indicating a potential upside of 146.02%. Given Gyre Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Gyre Therapeutics is more favorable than Medical Marijuana.
Profitability
This table compares Gyre Therapeutics and Medical Marijuana’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Gyre Therapeutics | -15.47% | -6.57% | -5.35% |
| Medical Marijuana | N/A | N/A | N/A |
Summary
Gyre Therapeutics beats Medical Marijuana on 6 of the 11 factors compared between the two stocks.
About Gyre Therapeutics
Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.
About Medical Marijuana
Medical Marijuana, Inc., an investment holding company, operates in the cannabinoid-based nutraceutical industry. It focuses on the development, sale, and distribution of hemp oil that contains naturally occurring cannabinoids, including cannabidiol (CBD) and other products containing CBD-rich hemp oil; treatment of pain and other medical disorders with the application of chewing gum-based cannabis/cannabinoid medical products; and nonpsychoactive cannabidiol products. The company is also involved in the research and development of new therapeutic agents that are designed to reduce oxidative stress and act as immuno-modulators and neuroprotectants; dietary supplements, skin care products, and prescription-based hemp oil under the Kannaway and HempMeds brands; and proprietary testing, genetics, labeling and packaging, tracking, and production and standardization methods for the medicinal cannabinoid industry. In addition, it offers RSHO oil for the treatment of various illnesses and conditions; and plant-based, non-GMO pet products for health and wellness, play and wear, and environmentally-friendly supplies. Medical Marijuana, Inc. was incorporated in 2005 and is based in San Diego, California.
Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
